The US FDA has approved AstraZeneca's FluMist nasal spray for at-home use which offers a needle-free option for flu vaccination. Designed for individuals aged 2 to 49, the vaccine can be self-administered or given by caregivers and is as effective as traditional flu shots in preventing influenza subtypes A and B. Experts believe this convenient method will increase vaccination coverage and reduce the spread of flu and its complications.

Source: Indian Express - September 23, 2024